Novo Nordisk had a record-breaking 2021 profit, but has reined in expectations for 2022

In 2021, Novo Nordisk has lifted both its revenue and profits to new heights, driven by great progress of its diabetes flagship semaglutide in both tablet and injection form. There are challenges ahead, however, the company warns, as it predicts less progress in 2022.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
By Mikkel Aabenhus Hemmingsen, translated by Daniel Pedersen

2021 was a historically good year for Novo Nordisk, which has never achieved such high revenue and profit results before, the company’s full-year report, released on Wednesday morning, states.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading